Feedback Share Discussion Threads

[lr2] 15/7/2019 09:46

The latest flurry of buys has broken it Duc.

Now - Buy 200k at 0.8943p.

[ducatiman] 15/7/2019 09:25

Crazy overhang, bewildering.

[lr2] 15/7/2019 09:21

Current on line limits are:
Sell 300k at 0.8165p (small amounts the same)
Buy 1 mil at 0.862p (small amounts the same)

[lr2] 15/7/2019 08:12

Role of MR texture analysis in histological subtyping and grading of renal cell carcinoma: a preliminary study.

[ducatiman] 14/7/2019 13:22

"and some" indeed Gym!

[gymratt] 14/7/2019 13:11

Yup, positive anticipation building up here. Innovative products, massive potential and I see FDBK going the same way as IQAI re; share price action.. and some...

[ducatiman] 14/7/2019 12:25

I am actually looking forward to next week, been a while since I felt that way with this stock!

[lr2] 13/7/2019 17:26

Siemens reckon "The average system lifespan of a PACS system lies between six and 10 years. Furthermore, IT changes and regulatory requirements start to diminish the efficiency almost right away."



Cadran can conquer the PACS universe 10% - 17% a year if it's ahead of the rest of the pack.

[bobd29] 13/7/2019 16:11

Hi ged you may be right, I will email TO to try and clarify. If I get an answer I’all put it here.

[ged5] 13/7/2019 14:02

Not sure that CADRAN is needed as a PACS for this to work. At least I hope not. I wouldn't want users to be put off by £120000 up front payment. There could be a lot more at stake here.

Looking at the potential market TO talked about over 100 hospitals in the UK with each hospital having 3000-4000 users. With a monthly payment of as little as £5 that's an annual income of £1.5M to £2M. Double the payment to £10 and you have more than our Mkt Cap.

But then he talks about the 15 million doctors worldwide. That's a potential market of a staggering £1.8 Billion annually with just a £10 monthly payment.

Check the video from about 5 minutes. He only talks about the number of potential users but put in your own monthly payments and start salivating!

[ducatiman] 13/7/2019 11:51

Cheers bob, if so and the product has demand, the ongoing revenue would be amazing!! Only fdbk can supply!!
A new innovative product in "September"
Texrad review ongoing which I am sure will lead to the fast tracking of a clinical model.
FDA application.
Certainly very exciting times ahead.
Hopefully the "sleeping giant" will awake from its slumbers soon.
Whoever is selling/shorting must be desperate and very short sighted indeed.
Some interesting weeks/months ahead of us.
GLA duc.

[bobd29] 13/7/2019 11:03

Hi duc, my understanding was that Cadran was the basis from which data could be exported to mobile basis both securely and in full clinical resolution. So Cadran woukd be essential to the process. Anyone with a different viewpoint?

[gymratt] 12/7/2019 16:34

Nice to get them under a penny. I'm not patting myself on the back just yet as my average is 1.4p ,so still well under water.

[gymratt] 12/7/2019 16:23

Be very nice if they reach my TP, Davy. ;@)

[davydoo] 12/7/2019 16:19

nearly 1% of the company, nice :)

[gymratt] 12/7/2019 16:13

Thanks Ged. But this one is the potential life changer. Well loaded up here with over 3 million shares. Two million of which are tucked away in the ISA.
;@)

[ged5] 12/7/2019 15:00

A good day for you, Gymratt. Well done!

[petekand] 12/7/2019 14:45

Yes it is.
But very importantly this time supported by what looks a very good innovative product.